IDEXX Laboratories, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael Erickson
- Full Time Employees
- 11,000
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- One IDEXX Drive Westbrook ME United States 04092
- IPO Date
- Jun 21, 1991
- CIK
- 0000874716
- Website
- idexx.com
- Similar Companies
- Business
- IDEXX Laboratories, Inc. (IDXX) develops, manufactures, and distributes diagnostic products, equipment, and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing industries. The company offers an extensive portfolio of in-clinic analyzers including the Catalyst One Chemistry Analyzer, ProCyte Dx Hematology Analyzer, SediVue Dx Urine Sediment Analyzer, and SNAP point-of-care tests; reference laboratory services for advanced diagnostics; veterinary software solutions such as IDEXX Neo and Cornerstone practice management software, VetLab Station laboratory information management system, and client communication tools; diagnostic imaging systems like ImageVue DR50 and EliteVision; and specialized tests for ruminants (e.g., BVDV, IBR/BHV-1, Johne's Disease), poultry (e.g., IBV, IBD), swine (e.g., PRRS, PEDV), equine health (e.g., EHV-1/4 RealPCR, EPM tests), and water quality microbiological detection serving over 2.5 billion people. IDEXX also provides OPTI Medical Systems for human point-of-care and laboratory diagnostics. Founded in 1983 and headquartered in Westbrook, Maine, the company operates in over 175 countries through its three main segments: Companion Animal Group (CAG), Water, and Livestock, Poultry, and Dairy (LPD), with additional EMEA headquarters in Hoofddorp, Netherlands, and approximately 10,000 employees worldwide. Recent developments include the strong adoption of the inVue Dx Cellular Analyzer with over 2,400 units installed in Q2 2025, surpassing expectations and prompting a full-year installation forecast increase to 5,500 units; the June 2025 launch of the Catalyst Cortisol Test, the third Catalyst platform expansion that year, enhancing point-of-care diagnostics for endocrine disorders like Addison's and Cushing's disease in dogs; the North American rollout of IDEXX Cancer Dx; upward revisions to 2025 revenue guidance to $4.27 billion-$4.30 billion and EPS to $12.81-$13.01 amid 11% Q2 revenue growth and 13% Q3 growth driven by recurring CAG diagnostics; and sustained R&D investment at about 5.75% of revenue to support platform expansions, AI-driven solutions, molecular tests, international commercial footprint growth in three countries by 2026, and software enhancements.
Company News
IDEXX Laboratories: Great Company, But Too Expensive (Rating Downgrade)
IDEXX Laboratories: Q3 Results Confirm They Are Best-In-Class
Idexx Laboratories (IDXX) Crossed Above the 200-Day Moving Average: What That Means for Investors
IDEXX Soars 20.2% on Earnings Beat: What It Means for Your S&P 500 Index Fund
IDEXX Laboratories, Inc. (IDXX) Q3 2026 Earnings Call Transcript
Aging Pets, Higher Testing Frequency Propel IDEXX Past Wall Street Estimates Despite Slower Clinic Traffic
IDEXX raises forecast, betting diagnostics can offset weak vet visits
IDEXX Sales Rise 10% as Margin Outlook Slips: Rapid Earnings Reaction
IDEXX Laboratories Q3 Earnings Call Highlights
Idexx (IDXX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
IDXX Q3 Earnings & Revenues Surpass Estimates, Stock Up in Pre-Market
IDEXX Laboratories, Perion Network, TAT Technologies And Other Big Stocks Moving Higher On Monday
Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue Estimates
IDEXX Laboratories Announces Third Quarter Results
Gear Up for Idexx (IDXX) Q3 Earnings: Wall Street Estimates for Key Metrics
IDEXX Laboratories, Inc. $IDXX Shares Purchased by Citizens Financial Group Inc. RI
Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth
Here's How IDEXX Laboratories Is Placed Ahead of Q3 Earnings
IDEXX Laboratories, Inc. $IDXX Shares Acquired by Diversify Advisory Services LLC
Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?